NASDAQ:LEGN Legend Biotech (LEGN) Stock Price, News & Analysis $22.30 -0.23 (-1.02%) Closing price 04:00 PM EasternExtended Trading$22.30 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Legend Biotech Stock (NASDAQ:LEGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Legend Biotech alerts:Sign Up Key Stats Today's Range$22.04▼$22.9650-Day Range$17.00▼$22.6052-Week Range$16.24▼$37.50Volume2.37 million shsAverage Volume2.40 million shsMarket Capitalization$4.32 billionP/E RatioN/ADividend YieldN/APrice Target$54.69Consensus RatingModerate Buy Company Overview Legend Biotech Corporation (NASDAQ: LEGN) is a biotechnology company focused on developing, manufacturing and commercializing cell therapies for cancer and other serious diseases. The company’s primary technology is chimeric antigen receptor T-cell (CAR-T) therapy, which genetically modifies a patient’s immune cells to recognize and attack cancer cells. Legend Biotech’s leading product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. The product was developed through a global collaboration with Janssen Biotech, part of Johnson & Johnson, and has received regulatory approvals in multiple markets. Legend is also advancing additional cell-therapy candidates targeting hematologic malignancies and other potential applications. Founded in 2014, Legend Biotech operates internationally, with research, development and manufacturing activities supporting the development and supply of its therapies in major pharmaceutical markets. The company is headquartered in Somerset, New Jersey, and is led by Chief Executive Officer Ying Huang.AI Generated. May Contain Errors. Read More Legend Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreLEGN MarketRank™: 3.70389476399 of 5 starsLegend Biotech scored higher than 74% of companies evaluated by MarketBeat, and ranked 175th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingLegend Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on no strong buy ratings, 9 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialLegend Biotech has a consensus price target of $54.69, representing about 145.3% upside from its current price of $22.30.Amount of Analyst CoverageLegend Biotech has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Legend Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Legend Biotech are expected to grow in the coming year, from ($0.08) to $1.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Legend Biotech is -89.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Legend Biotech is -89.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLegend Biotech has a P/B Ratio of 4.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Legend Biotech's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.18% of the float of Legend Biotech has been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Legend Biotech has recently decreased by 15.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLegend Biotech does not currently pay a dividend.Dividend GrowthLegend Biotech does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.96 News SentimentLegend Biotech has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Legend Biotech this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for LEGN on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows6 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Legend Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $308,550.00 in company stock.Percentage Held by Insiders0.02% of the stock of Legend Biotech is held by insiders.Percentage Held by Institutions70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Legend Biotech's insider trading history. Receive LEGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LEGN Stock News HeadlinesLegend Biotech (LEGN) Stock Could Trade Below Its Sales BackdropOctober 28 at 7:20 AM | finance.yahoo.comLegend Biotech to Host Investor Conference Call on Third Quarter 2026 ResultsOctober 27 at 8:00 AM | globenewswire.comElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracking a new Elon Musk project he calls the most epic AI initiative in history. The plan could give Musk access to 50 times more computing power than the rest of the world combined, a development Brown says is drawing attention from executives at Amazon, Microsoft, and Google. Brown compares the scale of this project to the SpaceX IPO, which minted thousands of millionaires overnight.October 29 at 1:00 AM | Brownstone Research (Ad)Legend Biotech: Carvykti Makes Billions, But The Profits Are ElusiveOctober 22, 2026 | seekingalpha.comHC Wainwright Forecasts Stronger Earnings for Legend BiotechOctober 18, 2026 | americanbankingnews.comLegend Biotech Wins FDA IND Clearance for First Dual-Target In Vivo CAR-T LB2501October 17, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN) and UnitedHealth (UNH)October 15, 2026 | theglobeandmail.comInsider Selling: Legend Biotech (NASDAQ:LEGN) Director Sells $258,920.20 in StockOctober 2, 2026 | insidertrades.comSee More Headlines LEGN Stock Analysis - Frequently Asked Questions How have LEGN shares performed this year? Legend Biotech's stock was trading at $21.74 at the beginning of 2026. Since then, LEGN stock has increased by 2.6% and is now trading at $22.30. How were Legend Biotech's earnings last quarter? Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) released its quarterly earnings data on Tuesday, August, 11th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.02. The company's quarterly revenue was up 51.9% on a year-over-year basis. Read the conference call transcript. When did Legend Biotech IPO? Legend Biotech (LEGN) raised $350 million in an IPO on Friday, June 5th 2020. The company issued 18,425,000 shares at $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO. Who are Legend Biotech's major shareholders? Top institutional investors of Legend Biotech include Sumitomo Mitsui Trust Group Inc. (0.09%), Oppenheimer & Co. Inc. (0.01%), Vontobel Holding Ltd. (0.01%) and China Universal Asset Management Co. Ltd. (0.01%). Insiders that own company stock include Ying Huang and Carlos E Santos. View institutional ownership trends. How do I buy shares of Legend Biotech? Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Legend Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Legend Biotech investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Micron Technology (MU), CRISPR Therapeutics (CRSP), Rocket Lab (RKLB), Oklo (OKLO) and AST SpaceMobile (ASTS). Company Calendar Last Earnings8/11/2026Today10/29/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 LEGN's financial health is in the Red zone, according to TradeSmith. LEGN has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LEGN CIK1801198 Webwww.legendbiotech.com Phone732-317-5050FaxN/AEmployees2,965Year Founded2014Price Target and Rating Average Price Target for Legend Biotech$54.69 High Price Target$74.00 Low Price Target$24.00 Potential Upside/Downside+146.9%Consensus RatingModerate Buy Rating Score (0-4)2.53 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$296.80 million Net Margins-7.21% Pretax Margin-4.42% Return on Equity-8.71% Return on Assets-5.40% Debt Debt-to-Equity RatioN/A Current Ratio3.04 Quick Ratio2.94 Sales & Book Value Annual Sales$1.27 billion Price / Sales3.38 Cash FlowN/A Price / Cash FlowN/A Book Value$5.43 per share Price / Book4.08Miscellaneous Outstanding Shares193,769,000Free Float193,730,000Market Cap$4.29 billion OptionableOptionable Beta0.57 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:LEGN) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredxIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't whole again un...USA Capital Gold | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Corporation Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
